← Back to Search

Behavioral Intervention

MAPP for Anxiety Disorders in Children (MAPP Trial)

N/A
Recruiting
Led By Golda S Ginsburg, PhD
Research Sponsored by UConn Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
6-17 years of age
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up youth will be assessed at 2 months (post intervention) and 6 months after eligibility is established.
Awards & highlights

Summary

This trial aims to help pediatric primary care providers help kids who are struggling with anxiety.

Who is the study for?
This trial is for children aged 6-17 who show signs of anxiety, with scores indicating mild to moderate symptoms. It's designed to help pediatricians better support these kids, especially where mental health resources are scarce.
What is being tested?
The MAPP clinical trial is testing a brief intervention called the Anxiety Action Plan (AxAP), aimed at reducing anxiety in children. Pediatric care providers will be trained and compared using AxAP versus Enhanced Usual Care involving educational materials.
What are the potential side effects?
Since this study involves non-medical interventions like training and educational materials, traditional physical side effects are not expected; however, there may be emotional or psychological responses unique to each child.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 6 and 17 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~youth will be assessed at 2 months (post intervention) and 6 months after eligibility is established.
This trial's timeline: 3 weeks for screening, Varies for treatment, and youth will be assessed at 2 months (post intervention) and 6 months after eligibility is established. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Clinical Global Impression Improvement scale
Primary Care Provider

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Managing Anxiety in Pediatric Primary Care (MAPP)Experimental Treatment1 Intervention
Participants receive approximately 4 sessions of a primary care provider-delivered intervention for reducing youth anxiety symptoms based on exposure therapy.
Group II: Enhanced Usual Care (EUC)Placebo Group1 Intervention
Participants receive a list of resources on how to reduce anxiety (e.g., videos, books, etc.).

Find a Location

Who is running the clinical trial?

UConn HealthLead Sponsor
212 Previous Clinical Trials
60,729 Total Patients Enrolled
2 Trials studying Anxiety
134 Patients Enrolled for Anxiety
National Institute of Mental Health (NIMH)NIH
2,869 Previous Clinical Trials
2,777,476 Total Patients Enrolled
86 Trials studying Anxiety
40,263 Patients Enrolled for Anxiety
National Institutes of Health (NIH)NIH
2,765 Previous Clinical Trials
8,133,451 Total Patients Enrolled
14 Trials studying Anxiety
19,182 Patients Enrolled for Anxiety
~37 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top